Business Context and Reporting Period
This Form 8-K Current Report was filed by Herbalife Ltd. on December 30, 2005. The filing discloses the entry into a material definitive agreement regarding the adoption of a new compensation plan for independent directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new director compensation plan.
Material Changes
The Board of Directors approved the "Herbalife Ltd. Independent Directors Deferred Compensation and Stock Unit Plan" on December 30, 2005. Key terms include:
- Initial Grant: On January 15, 2006, each independent director will receive restricted stock units (RSUs) valued at $100,000 based on the fair market value of common shares on that date.
- Annual Grants: Beginning January 15, 2007, continuing annual grants of $100,000 in RSUs will be made to directors who have served continuously since the prior year's grant date.
- Vesting: RSUs vest in four equal quarterly installments over 12 months following the grant date.
- Deferral and Distribution: Directors may defer distribution. Three years after the grant date, they may elect to have the value hypothetically invested in deemed alternatives or remain invested in company stock. Distributions generally cannot occur before the third anniversary of the grant date unless the director terminates service.
- Eligible Participants: As of the filing date, eligible independent directors are Leroy Barnes, Richard Bermingham, Peter Maslen, and Charles Orr.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary contingency noted is that the plan description is qualified by reference to the full text of the Plan and Stock Unit Agreement attached as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the exact number of shares issued for the $100,000 RSU grants based on the share price on January 15, 2006.
- Review the full text of the Plan (Exhibit 10.1) for specific investment alternatives available for deferred amounts.
- Confirm the total number of independent directors eligible for future annual grants to assess ongoing equity dilution.
- Check subsequent filings for the actual vesting schedule and any early terminations affecting distribution rights.